期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

对卵巢恶性肿瘤标志物的再认识 被引量：4

下载PDF
导出
摘要 肿瘤标志物（tumor marker）狭义的概念是指肿瘤细胞异常表达所产生的抗原或由于肿瘤存在而出现在患者体内的某种生物活性物质。近年来,文献提出生物标志物（biomarker）应作为一种广义的概念。即指作为一种指示因子,
作者 李小平 魏丽惠
机构地区 北京大学人民医院妇产科
出处 《中国妇产科临床杂志》 2011年第4期241-243,共3页 Chinese Journal of Clinical Obstetrics and Gynecology
关键词 肿瘤标志物 恶性 卵巢 生物活性物质 生物标志物 异常表达 肿瘤细胞
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer bi- omarker performance in prostate, lung, colorectal, and ovari- an cancer screening trial specimens. Cancer Prey Res, 2011, 4:365 - 374.
  • 2Zhu CS, Pinsky PF, Cramer DW, et ah A framework for evaluating biomarkers for early detection: validation of bio- marker panels for ovarian cancer. Cancer Prey Res, 2011, 4: 375 -483.
  • 3Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum--based biomarkers for early ovarian cancer detection. Cancer Prev Res, 2011, 4:303 - 306.
  • 4Jambs I, Menon U. The sinequanon of discovering novel biomark- ers for early detection of ovarian cancer: carefully selected preclinical samples CancerPrevRes, 2011, 4: 299-302.
  • 5Amonkar SD, Bertenshaw GP, Chen TH, et al. Develop- ment and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoSOne, 2009, 4: e4599.
  • 6Fioretti P, Gadducei A, Ferdeghini M, et al. The concomi- tant determination of different serum tumor markers in epi- thelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol, 1992, 44: 155-160.
  • 7董丽,李小平,崔恒,王建六,魏丽惠,赵彦,王世军,王悦,孙秀丽,梁旭东,李艺.卵巢上皮性癌血清肿瘤标志物谱变化的临床意义[J].中华妇产科杂志,2009,44(2):121-125. 被引量：7
  • 8Dean M, Fojo T, Bates S, et al. Tumor stem cells and drug resistance. Nat Rev Cancer, 2005, 5:275 - 284.
  • 9Nossov V, Amneus M, So F, et al. The early detection of o- varian cancer: from traditional methods to proteomics. Can we really do better than serum CAlzs. Am J Obstet Gynecol, 2008, 199: 215-223.

二级参考文献18

  • 1陈洁,刘鸣,汤春生.人卵巢癌细胞系具有不同转移潜能亚系的分离及体内和体外鉴定[J].实用妇产科杂志,2005,21(6):350-352. 被引量：8
  • 2Ovarian cancer: screening, treatment, and followup. NIH Consens Statement, 1994, 12 : 1-30.
  • 3Gadducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer, 2007,17:21-31.
  • 4Cheung VG, Conlin LK, Weber TM, et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet ,2003,33:422-425.
  • 5Tuxen MK, Soletormos G, Petersen PH, et al. Assessment of biological variation and analytical imprecision of CA125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol, 1999,74 : 12-22.
  • 6Berchuck A, O1t GJ, Soisson AP, et al. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol, 1990,162:883-888.
  • 7Tangjitgamol S, See HT, Manusirivithaya S, et al. Third-line chemotherapy in platinum- and paelitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Caneer,2004 ,14 :804-814.
  • 8Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA125 : a North Thames Ovary Group study. Ann Oncol, 1996, 7:361-364.
  • 9Fioretti P, Gadducci A, Ferdeghini M, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol, 1992,44 : 155-160.
  • 10Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 2005,99:267-277.

共引文献6

同被引文献32

  • 1廖琪,马晓艳.联合检测CA125、CA72-4和TSGF在卵巢癌诊断中的价值[J].中国医师杂志,2007,9(2):257-258. 被引量：3
  • 2Li F,Tie R,Chang K,et al. Does risk for ovarian malig- nancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer,a meta-anal- ysis[J]. BMC Cancer, 2012,12(2) . 258.
  • 3Yu S,Yang HJ,Xie SQ,et al. Diagnostic value of HE4 for ovarian cancer: a meta-analysis[J]. Clin Chem Lab Med, 2012,50(8) : 1439-1446.
  • 4Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant hu- man tissues[J]. Mod Pathol,2006,19 (6) : 847-853.
  • 5Speeckaert MM,Speeckaert R,Delanghe JR. Human epididy- mis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem, 2013,59 (1) : 1-21.
  • 6Sandri MT,Bottari F, Franchi D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass, correlation with pathological outcome[J]. Gynecol Oncol, 2013,128(2) ,233-238.
  • 7Trudel D, Ttu B, Gr6goire J, et al. Human epididymis protein 4(HE4) and ovarian cancer prognosis r J. Gynecol Oneol, 2012,127(3) :511-515.
  • 8Park Y,Kim Y, Lee EY, et al. Reference ranges for HE4 and CA125 in a large Asian population by automated as- says and diagnostic performances for ovarian cancer[J]. Int J Cancer,2012,130(5) .1136-1144.
  • 9Bolstad N, Oijordsbakken M, Nustad K, et aI. Human epi- didymis protein 4 reference limits and natural variation in a Nordic reference population[J]. Tumour Biol, 2012,33 (1) .141-148.
  • 10Jacob F,Meier M,Caduff R,et al. No benefit from combi- ning HE4 and CA125 as ovarian tumor markers in a clini- cal setting[J]. Gynecol Oncol,2011,121(3) .487-491.

引证文献4

二级引证文献19

中国妇产科临床杂志
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部